Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ReDrugBC

Financiado

Cerrado

Novel therapeutic approaches based on drug repurposing for high risk non muscl...

Novel therapeutic approaches based on drug repurposing for high risk non muscle invasive bladder cancer driven by patients proteomic signatures Bladder Cancer (BC) is the costlier cancer type to manage, characterized by high recurrence and progression rates. Despite recent advancements, current BC therapeutic strategies remain suboptimal, mostly due to the disease molecul... ver más

31/05/2022

MOSAIQUES DIAGNOST...

163K€

Presupuesto del proyecto: 163K€

Líder del proyecto

MOSAIQUES DIAGNOSTICS GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-05-31

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

MOSAIQUES DIAGNOSTICS GMBH

162.81K€ | Lider

Proyectos interesantes

RTI2018-102134-A-I00

Medical Technol...

Data Science

109K€ Cerrado

TheranOMICS

Medical Technol...

Data Science

116K€ Cerrado

BioMedBC

Medical Technol...

Data Science

159K€ Cerrado

PCaProTreat

Medical Technol...

Data Science

171K€ Cerrado

DIPROMON

Medical Technol...

Data Science

5M€ Cerrado

TransPot

Medical Technol...

Data Science

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 26 meses Fecha Inicio: 2020-03-26
Fecha Fin: 2022-05-31

Líder del proyecto

MOSAIQUES DIAGNOSTICS GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 163K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Bladder Cancer (BC) is the costlier cancer type to manage, characterized by high recurrence and progression rates. Despite recent advancements, current BC therapeutic strategies remain suboptimal, mostly due to the disease molecular heterogeneity. Profiling at the transcriptomics and, very recently, proteomics levels, revealed the existence of a cross-omics conserved molecular signature marking progression from low to high risk non muscle invasive (NMIBC) and eventually muscle invasive disease. ReDrugBC targets to identify drugs, via drug repurposing, able to revert the aggressive molecular signature for NMIBC, hence tackling the disease at an earlier stage and on a more holistic manner. To address this state-of-the-art concept, ReDrugBC is divided into three highly interrelated strategic points: 1) drug identification (among existing compounds) for NMIBC based on the existent tissue molecular profiles analyzed in a multi-layer and multi-omics manner using specialized bioinformatics-drug prediction tools, 2) definition of impact of selected drugs on the functional properties of BC cell lines in vitro and 3) characterization and understanding of the drug impact on a molecular level, via the application of high-throughput proteomics analysis. This research program will be carried out in a research intensive SME-leader in clinical proteomics and multi-dimensional analysis, by a very active and promising young researcher originating from academia, in a multidisciplinary, implementation-oriented manner. Outreach activities include among others links to pharmaceutical companies and regulators to accelerate progress towards (pre-) clinical trials post-ReDrugBC. Collectively, the proposed approach in ReDrugBC paves the way for better treatment of NMIBC via drug selection based on the patient molecular signatures, while offering unique inter-sectorial training on translational research to a highly motivated young female researcher.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores